SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-23-227642
Filing Date
2023-09-01
Accepted
2023-09-01 16:08:56
Documents
8
Period of Report
2023-10-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A d502179ddef14a.htm DEF 14A 651497
2 GRAPHIC g502179dsp020.jpg GRAPHIC 262641
3 GRAPHIC g502179dsp021.jpg GRAPHIC 130973
4 GRAPHIC g502179g00m02.jpg GRAPHIC 23892
5 GRAPHIC g502179g00m15.jpg GRAPHIC 20785
6 GRAPHIC g502179g00m39.jpg GRAPHIC 60432
7 GRAPHIC g502179g00m40.jpg GRAPHIC 627987
8 GRAPHIC g502179g50v17.jpg GRAPHIC 39024
  Complete submission text file 0001193125-23-227642.txt   2227489
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38266 | Film No.: 231232596
SIC: 2834 Pharmaceutical Preparations